Mablink is present at BIO-Europe 2021
Edouard LEROY Chief Business Officer of Mablink, participates (digitally) in the next edition of the event BIO-Europe, held as a digital event from October 25 to 28, 2021. BIO-Europe is …
Mablink is invited to present at the 12th annual PEGS Europe Virtual summit (November 9-12, 2020)
Dr. Warren Viricel, our company’s Chief Scientific Officer, is invited to present Mablink’s PSARlink™ drug-linker technology at the 12th annual PEGS Europe Virtual summit (Lisbon, PT) on Tuesday, November 10, …
Mablink presents at the digital Next Generation Bioconjugates Summit (November 2-5, 2020)
Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
Mablink presents at World ADC Digital (September 15-18, 2020)
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.
Mablink will attend MEET2WIN in Bordeaux (6-7 May, 2020)
Mablink will take the opportunity to meet with pharmaceutical companies and investors during MEET2WIN, the European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer. Two vibrant days dedicated to oncology and innovation.
Mablink will be attending the World ADC congress in London (2-5 March, 2020)
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.